Design Therapeutics, Inc. — Director's Dealing 2021

Mar 26, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2021-03-25

Reporting Person: Xu Stella (Director, 10% Owner)
Reporting Person: Quan Venture Fund II, L.P. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (4439839)		Indirect
Series B Preferred Stock	$		Common Stock (280991)		Indirect

Footnotes

F1: All outstanding shares of Preferred Stock will automatically convert into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest.